Idorsia stock
IDIA.SWSIXIdorsia Ltd, HealthcareISIN CH0363463438
36Score 36 out of 100, Weak
Price and trend
37 / 100
Price history
+24% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 14% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 42).
The price is 43% below its 52-week high. Largest decline in 9 years: 98% (January 2020 to December 2024).
Chart figures for advanced users
- SMA 50$5.39
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.55
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)42
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.53
- The lowest closing price of the last twelve months.
- Resistance$8.30
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Idorsia Ltd belongs to the Biotechnology industry (Switzerland) and, with a market value of $1.28B, is number 172 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $266.31M (up 96.4% year on year) and a loss of $134.96M.
- For fiscal 2026, analysts expect on average revenue of $266.55M (up 0.1%) and adjusted earnings per share of −$0.87.
Show more
- MEQIRI Score 36 out of 100 (Weak): rank 617 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 50% since 2020.Capital allocation 18
- Loss-makingLoss of $341.88M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$142.17M over the last 12 months.Fundamentals 17
Its standout strength is growth, while fundamentals and stability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 35 to 36.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 5.2% on the twelve months before. Revenue turned from negative at the start of the period to positive ($266.31M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 82%, operating −59%, net −51%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 29 Oct 2026EPS reported −$0.18 (expected −$0.23)above expectations
Analyst estimates
- Earnings per share
- −$0.87+8.5%
- Revenue
- $266.55M−2.2%
- Earnings per share
- −$0.51+2.3%
- Revenue
- $353.47M+4.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Idorsia
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 36
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Inhibrx BiosciencesINBX $1.33B34
- GH ResearchGHRS $1.32B37
- COMPASS PathwaysCMPS $1.32B35
- OmerosOMER $1.31B52
- Alpha Tau MedicalDRTS $1.3B43
- Rapport TherapeuticsRAPP $1.3B33
- UroGen PharmaURGN $1.28B36
- Nektar TherapeuticsNKTR $1.27B29
ETFs that hold Idorsia
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.09% | 0.40% | €1.49B |
| iShares Ageing Population UCITS ETF2B77 | 0.08% | 0.40% | €807M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.07% | 0.30% | €3.43B |
Show 5 more
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.05% | 0.23% | €319.31M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2018)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.